



DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
SOUTHWEST REGION

m4152n

Office of the Regional
Food and Drug Director
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982
TELEPHONE: 214-655-8100
FACSIMILE: 214-655-8130

August 17, 2000

WARNING LETTER

**CERTIFIED MAIL
RETURN RECEIPT REQUESTED**

00-SWR-WL-78/0

Brent O'Brien
Radiology Director
Regional West Medical Center
4021 Avenue B
Scottsbluff, NE 69361

RE: Inspection ID - 1335120008

Dear Brent O'Brien:

On August 8, 2000, a representative of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility.

The Mammography Quality Standards Act of 1992 requires your facility to meet specific standards. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 and level 2 findings at your facility:

Level 1: Mammograms were processed in processor 1, Kodak, when it was out of limits on 5 days.

Level 2: The x-ray system for unit 4, Instrumentarium Imaging Corp., is not accredited.

Level 2: The medical physicist's surveys for x-ray units 2 & 3, General Electric Co. (GE Medical Systems) and unit 4, Instrumentarium Imaging Corp., are incomplete because the following tests were not done:

- No focal spot size/resolution measurement:
 - Test not done for all clinically used focal spots.
- No decompression.

Level 2: The medical physicist did not meet the requirement of conducting surveys for at least one facility and 10 units: [REDACTED]

Level 2: The medical physicist did not meet the requirement of having a minimum of 20 contact hours of training in conducting surveys: [REDACTED]

The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection.

Level 1 findings may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility. They represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to:

- Placing your facility under a Directed Plan of Correction.
- Charging your facility for the cost of on-site monitoring.
- Assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- Suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. You are required to respond to this office in writing within fifteen (15) working days from receipt of this letter. Please address the following:

- The specific steps you have taken to correct all of the violations noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.
- Equipment settings (including technique factors), raw test data, and calculated final results, where appropriate.
- Sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).


Please submit your response to:
Deborah M. McGee, Radiation Specialist
Food and Drug Administration
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982

This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

Page 3
August 17, 2000

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Deborah M. McGee at (214) 655-8100 ext. 138.

Sincerely yours,


Elaine Crosby
Acting Regional Food and Drug Director